相关实验视频
Updated: Jun 18, 2025

07:01
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
84.8K
通过低氧抑制CDK5RAP3激活P38MAPK以促进血管生成
Mengmeng Zhang1,2, Liu Yang3, Jun Shu1
1Department of Plastic and Reconstructive Surgery, Chinese PLA General Hospital.
International heart journal
|July 31, 2024
概括
CDK5RAP3是一种瘤抑制剂,通过降低缺氧下血管内皮生长因子 (VEGF) 来抑制血管生成. 它的下调促进VEGF,增强血管形成.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 在瘤学瘤学.
背景情况:
- CDK5RAP3通过抑制细胞循环激酶 (Chk1,Chk2) 和激活p53,对亡至关重要,起到瘤抑制作用.
- CDK5RAP3还调节p38 MAPK通路的活动,影响细胞应激反应.
研究的目的:
- 为了研究CDK5RAP3.3.的抗血管性潜力.
- 阐明CDK5RAP3在低氧条件下调节人类静脉内皮细胞 (HUVECs) 血管生成中的分子机制.
主要方法:
- 为了诱导血管生成,HUVECs被置于低氧条件 (2% O2) 中.
- 血管内皮生长因子 (VEGF) 用于刺激血管生成.
- 测量了CDK5RAP3,p38MAPK酸化和VEGF分泌的水平.
- 用低氧条件介质 (HCM) 进行了细胞增殖,迁移和管形成试验.
主要成果:
- 低毒性条件导致HUVECs中CDK5RAP3水平的时间依赖性下降.
- 减少的CDK5RAP3与增加的p38MAPK酸化和激活相关.
- 中度缺氧显著增加了VEGF分泌.
- HCM增强了HUVEC的扩散,迁移和管道形成.
结论:
- 中度缺氧通过抑制内皮细胞中的CDK5RAP3表达来促进血管生成.
- CDK5RAP3在血管再生中发挥着关键作用,其下调增强了VEGF合成和内皮细胞功能.
- CDK5RAP3显示出作为一种抗血管生成剂的潜力,用于涉及异常血管生成的疾病,如癌症,缺血性疾病和伤口愈合.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

